CII
ELOS

CR Intrinsic Investors’s Syneron Medical Ltd ELOS Stock Holding History

CR Intrinsic Investors’s Portfolio ELOS Stock Details ELOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-270,000
Closed -$2.33M – 416
2013
Q3 		$2.33M Buy
+270,000
New +$2.33M 0.07% 276

Other funds holding ELOS

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
HC
Hourglass Capital Houston, Texas $480M AUM 32.35% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CR Intrinsic Investors's ELOS Position: Q4 2013 in Review

CR Intrinsic Investors sold out of Syneron Medical Ltd (ELOS) in Q4 2013, closing a stake of 270,000 shares — an estimated $2.33M sold.

CR Intrinsic Investors first reported a position in ELOS in Q3 2013 and held it in 1 quarter. The position peaked at $2.33M in Q3 2013. 67 funds tracked by Wall St. Rank hold ELOS as of Q4 2013.

  • CR Intrinsic Investors reported no remaining Syneron Medical Ltd position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 270,000 Syneron Medical Ltd shares in Q4 2013, an estimated $2.33M.
  • CR Intrinsic Investors first reported a position in Syneron Medical Ltd in Q3 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's Syneron Medical Ltd position peaked at $2.33M in Q3 2013.
  • 67 funds tracked by Wall St. Rank held Syneron Medical Ltd as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.